Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.70M | 45.89M | 19.99M | 26.20M | 15.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.70M | 45.89M | 19.99M | 26.20M | 15.39M |
| Cost of Revenue | 5.83M | 7.36M | 8.11M | 10.49M | 11.45M |
| Gross Profit | 11.87M | 38.53M | 11.88M | 15.71M | 3.94M |
| SG&A Expenses | 17.72M | 18.52M | 18.33M | 18.43M | 18.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.55M | 25.88M | 26.45M | 28.92M | 29.82M |
| Operating Income | -5.85M | 20.01M | -6.46M | -2.73M | -14.43M |
| Income Before Tax | -6.47M | 73.07M | -2.89M | 73.21M | -14.14M |
| Income Tax Expenses | -1.54M | 12.04M | -6.50M | 18.37M | -559.00K |
| Earnings from Continuing Operations | -4.93M | 61.02M | 3.62M | 54.84M | -13.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.93M | 61.02M | 3.62M | 54.84M | -13.58M |
| EBIT | -5.85M | 20.01M | -6.46M | -2.73M | -14.43M |
| EBITDA | -5.47M | 20.41M | -6.05M | -2.32M | -14.02M |
| EPS Basic | -0.10 | 1.20 | 0.07 | 1.09 | -0.27 |
| Normalized Basic EPS | -0.03 | -0.64 | -0.04 | 0.91 | -0.18 |
| EPS Diluted | -0.10 | 1.15 | 0.07 | 1.08 | -0.27 |
| Normalized Diluted EPS | -0.03 | -0.61 | -0.03 | 0.90 | -0.18 |
| Average Basic Shares Outstanding | 51.28M | 50.87M | 50.52M | 50.18M | 49.71M |
| Average Diluted Shares Outstanding | 51.28M | 53.05M | 51.91M | 50.73M | 49.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |